Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-10-22 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about an upcoming Board Meeting scheduled for November 4, 2024, where the company will consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2024. It also mentions the trading window closure and reopening dates and announces an earnings call on the same day. The document does not contain actual financial data or results but is an announcement of the meeting and related events. The document length is short (1935 characters), and it serves as a notification rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification of upcoming financial results and events, not the financial report itself or the earnings release.
2024-10-22 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the appointment of a new Chief Executive Officer (CEO) of the company, including detailed biographical information and compliance with SEBI regulations. It specifically mentions the appointment of Mr. Shyamakant Giri as CEO effective January 15, 2025, and the continuation of Mr. Srinivas Sadu as Executive Chairman. The document references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in management. There are no financial statements, earnings data, or audit information present. The content is clearly an announcement of a change in senior management rather than a report or financial filing. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (5227 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2024-10-18 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges referencing a certificate under Regulation 74(5) of the SEBI (Depository and Participants Regulations), 2018. It mentions a Confirmation Certificate from the Registrar and Share Transfer Agent for the quarter ended September 30, 2024. The document is short (1582 characters) and primarily serves as a submission or confirmation letter rather than containing financial data or detailed report content. It does not contain financial statements or detailed analysis, nor is it a report itself. This fits the profile of a Regulatory Filing (RNS), which covers compliance documents and confirmations submitted to regulators or exchanges.
2024-10-16 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the closure of the trading window due to upcoming declaration of Un-Audited Financial Results for the quarter and half year ending September 30, 2024. It references the SEBI regulations on insider trading and mentions the date of closure and that the board meeting date will be intimated later. There are no actual financial statements or detailed financial data included. The document is essentially an announcement related to compliance and trading restrictions ahead of financial results, not the financial results themselves or a detailed report. The length is short (1522 characters), and it serves as a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice rather than an Interim Report or Earnings Release.
2024-09-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about the schedule of upcoming analyst and institutional investor meetings. It references regulatory compliance (SEBI Listing Obligations) and provides dates and types of meetings. The content is an announcement of meetings rather than a financial report, earnings release, or detailed investor presentation. The document length is short (1588 characters), and it does not contain financial data or detailed analysis. Therefore, it fits best under Investor Presentation (IP) as it relates to investor communication, but since it is only a schedule notification and not a detailed presentation, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about investor meetings without substantive financial content or presentation materials.
2024-09-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated September 12, 2024, addressed to stock exchanges regarding the schedule of an Analyst/Institutional Investor Meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content is purely an announcement of a meeting schedule with no financial data, analysis, or detailed presentation included. The document length is only 1549 characters, indicating it is a brief notice rather than a full report or presentation. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and disclosure rather than an Investor Presentation (IP) or any other detailed report type.
2024-09-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.